arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive Leaguearthyper-1311Research ArticleСтатьиArticlesГлюкозо-инсулиново-калиевая смесь при остром коронарном синдроме. Точку ставить раноЯковлевА. Н.noemail@neicon.ruНифонтовЕ. М.noemail@neicon.ruЩербакН. С.noemail@neicon.ruГалагудзаМ. М.galagoudza@mail.ruСанкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаRussian FederationФГУ «Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Росмедтехнологий»Russian Federation200828022008141-S2137146Copyright © Яковлев А.Н., Нифонтов Е.М., Щербак Н.С., Галагудза М.М., 20082008Яковлев А.Н., Нифонтов Е.М., Щербак Н.С., Галагудза М.М.Яковлев А.Н., Нифонтов Е.М., Щербак Н.С., Галагудза М.М.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1311

Глюкозо-инсулиново-калиевая смесь (ГИКС) используется в кардиологии с 1960-х годов, но на сегодняшний день данные об эффективности подобной терапии остаются противоречивыми. В обзоре освещены механизмы кардиопротективного действия компонентов ГИКС. результаты основных экспериментальных и крупных клинических исследований. Представлены собственные данные об эффективности терапии ГИКС у пациентов с острым коронарным синдромом без подъема сегмента ST, демонстрирующие улучшение сократительной функции миокарда и антиишемическое действие, а также возможную роль взаимодействия эффектов терапии ГИКС и эндогенных механизмов кардиопротекции.

глюкозо-инсулиново-калиевая смесьострый коронарный синдромReferencesApstein C.S. Metabolic approaches in ischaemic heart disease. Eur. Heart J. 1999; l (Suppl. O): Ol-O10.Apstein C.S. Metabolic approaches in ischaemic heart disease. Eur. Heart J. 1999; l (Suppl. O): Ol-O10.Rackley C.E., Russel R.O., Rogers W.J. et al. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am. Heart J. 1981; 102: 1038-1049.Rackley C.E., Russel R.O., Rogers W.J. et al. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am. Heart J. 1981; 102: 1038-1049.Eberli F.R., Weinberg E.O., Grice W.N. el al. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ. Res. 1991; 68: 466-481.Eberli F.R., Weinberg E.O., Grice W.N. el al. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ. Res. 1991; 68: 466-481.Oliver M., Opie I. Effect of glucose and fatty acids on myocardial ischemia and arrhytmias. Lancet. 1994; 343: 155-158.Oliver M., Opie I. Effect of glucose and fatty acids on myocardial ischemia and arrhytmias. Lancet. 1994; 343: 155-158.Ferrari R. Healthy versus sick myocites: metabolism, structure and function. Eur. Heart. J. 2002; 4 (Suppl. G): G1-G12.Ferrari R. Healthy versus sick myocites: metabolism, structure and function. Eur. Heart. J. 2002; 4 (Suppl. G): G1-G12.Lopaschuk G.D. Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart disease. Eur. Heart J. 1999; l (Suppl. O): 032-039.Lopaschuk G.D. Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart disease. Eur. Heart J. 1999; l (Suppl. O): 032-039.King L., Boucher F., Opie L.H. Coronary flow and glucose delivery as determinants of contracture in the ischemic myocardium. J. Mol. Cell. Cardiol. 1995; 27: 701-725.King L., Boucher F., Opie L.H. Coronary flow and glucose delivery as determinants of contracture in the ischemic myocardium. J. Mol. Cell. Cardiol. 1995; 27: 701-725.Kurien V., Yates P., Oliver M.F. Free fatty acids, heparin and arrythmias during experimental myocardial infarction. Lancet. 1969; 2: 185-187.Kurien V., Yates P., Oliver M.F. Free fatty acids, heparin and arrythmias during experimental myocardial infarction. Lancet. 1969; 2: 185-187.Das U.N. Insulin: an endogenous cardioprotector. Current opinion in critical care. 2003; 9: 475-383.Das U.N. Insulin: an endogenous cardioprotector. Current opinion in critical care. 2003; 9: 475-383.Chaudhuri A., Janicke D., Wilson M.F. et al. Antiinflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 2001; 109: 849-851.Chaudhuri A., Janicke D., Wilson M.F. et al. Antiinflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 2001; 109: 849-851.Hoedemaekers C.Y., Pickkers P., Netea M.G. et al. Intensive insulin therapy does not alter the inflammatory response in patients undergoing coronary artery bypass grafting: a randomized controlled i rial [ISRCTN95608630]. Critical Care. 2005; 9: R790-R797.Hoedemaekers C.Y., Pickkers P., Netea M.G. et al. Intensive insulin therapy does not alter the inflammatory response in patients undergoing coronary artery bypass grafting: a randomized controlled i rial [ISRCTN95608630]. Critical Care. 2005; 9: R790-R797.Yellon D.M., Baxter G.F. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distinct dream or near reality? Heart. 2000; 83: 381-387.Yellon D.M., Baxter G.F. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distinct dream or near reality? Heart. 2000; 83: 381-387.Jonassen A.К., Brar B.K., Mjos O.D. et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J. Mol. Cell. Cardiol. 2000: 32: 757-764.Jonassen A.К., Brar B.K., Mjos O.D. et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J. Mol. Cell. Cardiol. 2000: 32: 757-764.Jonassen A.К., Sack M.N., Mjos O.D. et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res. 2001; 89: 1191-1198.Jonassen A.К., Sack M.N., Mjos O.D. et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res. 2001; 89: 1191-1198.Gao F., Gao E., Yue T.L. et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of P13-kinase, Akt. and endothelial nitric oxide synthase phosphorylation. Circulation. 2002; 105: 1497- 1502.Gao F., Gao E., Yue T.L. et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of P13-kinase, Akt. and endothelial nitric oxide synthase phosphorylation. Circulation. 2002; 105: 1497- 1502.Zhang L., Zhang L., Li Y.H. et al. High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction. Eur. J. Clin. Invest. 2005; 35: 164-170.Zhang L., Zhang L., Li Y.H. et al. High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction. Eur. J. Clin. Invest. 2005; 35: 164-170.Sack M.N., Yellon D.M. Insulin therapy as an adjunct to reperfusion alter acute coronary ischemia a proposed direct myocardial cell survival effect independent of metabolic modulation. J. Am. Coll. Cardiol. 2003; 11: 1404-1407.Sack M.N., Yellon D.M. Insulin therapy as an adjunct to reperfusion alter acute coronary ischemia a proposed direct myocardial cell survival effect independent of metabolic modulation. J. Am. Coll. Cardiol. 2003; 11: 1404-1407.LaDisa J.F., Krolikowski J.G., Paged P.S. et al. Cardioprotection by glucose-insulin-potassiiim: dependence on KAPT channel opening and blood glucose con-cent ration before ischemia, Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H601-H607.LaDisa J.F., Krolikowski J.G., Paged P.S. et al. Cardioprotection by glucose-insulin-potassiiim: dependence on KAPT channel opening and blood glucose con-cent ration before ischemia, Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H601-H607.Folmes C.D., Clanachan A.S., Lopaschuk G.D. Fatty acids attenuate insulin regulation of 5'-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circulation Research. 2006; 99: 61-67.Folmes C.D., Clanachan A.S., Lopaschuk G.D. Fatty acids attenuate insulin regulation of 5'-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circulation Research. 2006; 99: 61-67.Kloner R.A., Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2001? J. Am. Coll. Cardiol. 2004; 44: 276-286.Kloner R.A., Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2001? J. Am. Coll. Cardiol. 2004; 44: 276-286.Oliver M.F. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am. J. Med. 2002; 112: 305-311.Oliver M.F. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am. J. Med. 2002; 112: 305-311.Liu J.G., Shu H., Shen F.M. Et al. Effects of glucose-insulin-potassium on baroreflex sensitivity, left ventricular function and ventricular arrhythmia in the subacute phase of myocardial infarction in rats. Fundam. Clin. Pharmacol. 2003; 17: 443-448.Liu J.G., Shu H., Shen F.M. Et al. Effects of glucose-insulin-potassium on baroreflex sensitivity, left ventricular function and ventricular arrhythmia in the subacute phase of myocardial infarction in rats. Fundam. Clin. Pharmacol. 2003; 17: 443-448.Angelos M.G., Murray H.N., Gorsline R.T. et al. Glucose, insulin and potassium(G1K) during reperfusion mediates improved myocardial biocnergetics. Resuscitation. 2002; 55: 329-336.Angelos M.G., Murray H.N., Gorsline R.T. et al. Glucose, insulin and potassium(G1K) during reperfusion mediates improved myocardial biocnergetics. Resuscitation. 2002; 55: 329-336.Нифонтов P.M., Щербак Н.С., Яковлев А.Н. и соавт. Кардиопротективные эффекты высокодозной глюкозо-инсулино-калиевой смеси и ишемического прекондиционирования и эксперименте на модели изолированного сердца крысы. Кардиология СНГ. 2005; 3 (2): 154-159.Нифонтов P.M., Щербак Н.С., Яковлев А.Н. и соавт. Кардиопротективные эффекты высокодозной глюкозо-инсулино-калиевой смеси и ишемического прекондиционирования и эксперименте на модели изолированного сердца крысы. Кардиология СНГ. 2005; 3 (2): 154-159.Kones R.J., Glucose, insulin, and potassium therapy for heart disease. History of GIK therapy. New York Stale J. Med. 1975: 75: 1463-1492.Kones R.J., Glucose, insulin, and potassium therapy for heart disease. History of GIK therapy. New York Stale J. Med. 1975: 75: 1463-1492.Fath-Ordoubadi F., Beatt K.J. Glucose-insulin-potassium (GIК) therapy for treatment of acute myocardial infarction: an overwiev of randomised placebo controlled trials. Circulation. 1997: 90: 1152-1150.Fath-Ordoubadi F., Beatt K.J. Glucose-insulin-potassium (GIК) therapy for treatment of acute myocardial infarction: an overwiev of randomised placebo controlled trials. Circulation. 1997: 90: 1152-1150.Diaz R., Paolasso E., Piegas I. et al. Metabolic modulation of acute myocardial infarction: the ECLA Glucose Insulin Potassium Pilot Trial. Circulation. 1998; 98: 2227-2231.Diaz R., Paolasso E., Piegas I. et al. Metabolic modulation of acute myocardial infarction: the ECLA Glucose Insulin Potassium Pilot Trial. Circulation. 1998; 98: 2227-2231.Malmberg K., Ryden L, Hamsten A. et al. Effects of insulin treatment on cause-specific one-year mortality in diabetic patients with acute myocardial infarction. DIGAMI study group. Eur. Heart J. 1990; 17: 1337-1344.Malmberg K., Ryden L, Hamsten A. et al. Effects of insulin treatment on cause-specific one-year mortality in diabetic patients with acute myocardial infarction. DIGAMI study group. Eur. Heart J. 1990; 17: 1337-1344.Candey A. High-dose CI К does not improve mortality. www.theheart.org. - Nov 8, 2001.Candey A. High-dose CI К does not improve mortality. www.theheart.org. - Nov 8, 2001.Pache J., Kastrati A., Mehilli J. et al. Metabolic protection with glucose-insulin-potassium infusion in patients with acute myocardial infarction. Eur. Heart J. 2002: 1 (Abstr. Suppl.): 586.Pache J., Kastrati A., Mehilli J. et al. Metabolic protection with glucose-insulin-potassium infusion in patients with acute myocardial infarction. Eur. Heart J. 2002: 1 (Abstr. Suppl.): 586.van der Horst I.C., Zijlstra P., van't Hof A.W. et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: a randomized trial. J. Am. Coll. Cardiol. 2003; 42: 784-781.van der Horst I.C., Zijlstra P., van't Hof A.W. et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: a randomized trial. J. Am. Coll. Cardiol. 2003; 42: 784-781.Mehta S.R., Yusuf S., Diaz R. et al. Effect of glucose-insulm-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarct ion. The СREАТЕ-ECLA randomized controlled trial. J.A.M.A. 2005: 293: 437-446.Mehta S.R., Yusuf S., Diaz R. et al. Effect of glucose-insulm-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarct ion. The СREАТЕ-ECLA randomized controlled trial. J.A.M.A. 2005: 293: 437-446.Schiller N.B., Sbab P.M., Crawford M. etal. Recommendations for quantitation of the left ventricle by two dimensional echocardiography. J. Am. Soc. Pchocardiogr. 1989; 2: 358-367.Schiller N.B., Sbab P.M., Crawford M. etal. Recommendations for quantitation of the left ventricle by two dimensional echocardiography. J. Am. Soc. Pchocardiogr. 1989; 2: 358-367.Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 310: 1111-1115.Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 310: 1111-1115.Hirooka Y., Egashira K., Imaizumi T. et al. Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and Forearm vasculatures in humans. J. Am. Coll. Cardiol. 1991; 21: 948-55.Hirooka Y., Egashira K., Imaizumi T. et al. Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and Forearm vasculatures in humans. J. Am. Coll. Cardiol. 1991; 21: 948-55.Иванова О.В., Рогоза A.Н., Балахонова Т.В. и соавт. Определение чувствительности плечевой артерии к напряжению сдвига па эндотелии как метод оценки состояния эндотелийзависимой вазодилатадии с помощью ультразвука высокого разрешения у больных с артериальной гипертонией. Кардиология. 1998: 6: 37-40.Иванова О.В., Рогоза A.Н., Балахонова Т.В. и соавт. Определение чувствительности плечевой артерии к напряжению сдвига па эндотелии как метод оценки состояния эндотелийзависимой вазодилатадии с помощью ультразвука высокого разрешения у больных с артериальной гипертонией. Кардиология. 1998: 6: 37-40.Оганов Р.Г., Агапов А.А., Акчурин Р.С. и соавт. Лечение острых коронарных синдромов без стойких подьёмов сегмента ST на ЭКГ. Consilium Medicum. 2001: 3: 4-15.Оганов Р.Г., Агапов А.А., Акчурин Р.С. и соавт. Лечение острых коронарных синдромов без стойких подьёмов сегмента ST на ЭКГ. Consilium Medicum. 2001: 3: 4-15.Heng M.K., Norris R.M.,Peter T. et al. The effect of glucose-insulin-potassium on experimental myocardial infarction in the dog. Cardiovasc. Res. 1978; 12: 429-35.Heng M.K., Norris R.M.,Peter T. et al. The effect of glucose-insulin-potassium on experimental myocardial infarction in the dog. Cardiovasc. Res. 1978; 12: 429-35.Castro P.F., Larrain G., Baeza R. et al. Effects of glucose-insulin-potassium solution on myocardial salvage and left ventricular function alter primary angioplasty. Crit Care Med. 2003; 31: 2152-2155.Castro P.F., Larrain G., Baeza R. et al. Effects of glucose-insulin-potassium solution on myocardial salvage and left ventricular function alter primary angioplasty. Crit Care Med. 2003; 31: 2152-2155.Diaz R., Goyal A., Mehta S.R. et al. Clucose-insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction. J.A.M.A. 2007; 298: 2399-2105.Diaz R., Goyal A., Mehta S.R. et al. Clucose-insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction. J.A.M.A. 2007; 298: 2399-2105.Apstein C.S. Glucose-insulin-potassium infusion and mortality in the CREATE- ECLA trial. J.A.M.A. 2005; 293: 2590-2597.Apstein C.S. Glucose-insulin-potassium infusion and mortality in the CREATE- ECLA trial. J.A.M.A. 2005; 293: 2590-2597.Schipke J.D., Friebe R., Gams P. Forty years of glucose-insulin-potassium (GIK) in cardiac surgery: a review of randomized, controlled trials. Eur. J. Cardiothorac. Surg. 2000; 29: 479-485.Schipke J.D., Friebe R., Gams P. Forty years of glucose-insulin-potassium (GIK) in cardiac surgery: a review of randomized, controlled trials. Eur. J. Cardiothorac. Surg. 2000; 29: 479-485.Ayala Т.Н., Schulman S.P. Pathogenesis and early management of non-ST-segment elevation acute coronary syndromes. Cardiol. Clin. 2006; 24: 19-35.Ayala Т.Н., Schulman S.P. Pathogenesis and early management of non-ST-segment elevation acute coronary syndromes. Cardiol. Clin. 2006; 24: 19-35.Elbaz M., Carrie D., Baudeux J.L. et al. High frequency of endothelial vasomotor dysfunction after acute coronary syndromes in non-culprit and angiographically normal coronary arteries: a reversible phenomenon. Atherosclerosis. 2005; 181: 311 -319.Elbaz M., Carrie D., Baudeux J.L. et al. High frequency of endothelial vasomotor dysfunction after acute coronary syndromes in non-culprit and angiographically normal coronary arteries: a reversible phenomenon. Atherosclerosis. 2005; 181: 311 -319.Chowienczyk P.J., Watts G.F., Cockroft J.R. et al. Impaired endothelium dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 1992: 340: 1430-1432.Chowienczyk P.J., Watts G.F., Cockroft J.R. et al. Impaired endothelium dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 1992: 340: 1430-1432.Ludmer P.L., Selwyn A.P., Shook T.L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerosis coronary arteries. New Engl. Journ. Med. 1986: 315: 1046-1051.Ludmer P.L., Selwyn A.P., Shook T.L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerosis coronary arteries. New Engl. Journ. Med. 1986: 315: 1046-1051.Vaughan D.E. Endothelial function, fibrinolysis, and angiotensyn-converting enzym inhibition. Clin. Cardiology. 1997; 20 (Suppl. II): II-34-II-37.Vaughan D.E. Endothelial function, fibrinolysis, and angiotensyn-converting enzym inhibition. Clin. Cardiology. 1997; 20 (Suppl. II): II-34-II-37.Meijering S., Corstjens A., Tulleken J.P. et al. Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature. Crit. Care. 2000; 10: 19-27.Meijering S., Corstjens A., Tulleken J.P. et al. Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature. Crit. Care. 2000; 10: 19-27.Chaudhuri A., Janicke D., Wilson M. et al. Effect of modified glucose-insulin-potassium on free fatty acids, matrix metalloprotcinase, and myoglobin in ST-elevation myocardial infarction. Am. J. Cardiol. 2007; 100: 1614-1618.Chaudhuri A., Janicke D., Wilson M. et al. Effect of modified glucose-insulin-potassium on free fatty acids, matrix metalloprotcinase, and myoglobin in ST-elevation myocardial infarction. Am. J. Cardiol. 2007; 100: 1614-1618.Ranasinghe A.M., McCabe C.J., Quinn D.W. et al. How does glucose insulin potassium improve hemodynamic performance? Evidence for altered expression of beta-adrenoreceptor and calcium handling genes. Circulation. 2006; 114 (Suppl. 1): 1239-1244.Ranasinghe A.M., McCabe C.J., Quinn D.W. et al. How does glucose insulin potassium improve hemodynamic performance? Evidence for altered expression of beta-adrenoreceptor and calcium handling genes. Circulation. 2006; 114 (Suppl. 1): 1239-1244.Celkan M.A., Kazaz H., Daglar B. et al. Effects of glucose-insulin-potassium solution on cardiac cytokines and enzymes. Thorac. Cardiovasc. Surg. 2000; 54: 532-530.Celkan M.A., Kazaz H., Daglar B. et al. Effects of glucose-insulin-potassium solution on cardiac cytokines and enzymes. Thorac. Cardiovasc. Surg. 2000; 54: 532-530.Bhayana V., Henderson A.R. Biochemical markers of myocardial damage. Clin. Biochem. 1995; 28: 1-29.Bhayana V., Henderson A.R. Biochemical markers of myocardial damage. Clin. Biochem. 1995; 28: 1-29.Khoury V.K., Haluska В., Prins J. et al. Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction. Heart (British Cardiac Society). 2003; 89: 61-65.Khoury V.K., Haluska В., Prins J. et al. Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction. Heart (British Cardiac Society). 2003; 89: 61-65.Yetkin E., Senen K. Ileri M. et al. Comparison of low-dose dobutamine stress echocardiography and echocardiography during glucose-insulin-potassium infusion for detection of myocardial viability after anterior myocardial infarction. Coronary Artery Disease. 2002: 13: 145-149.Yetkin E., Senen K. Ileri M. et al. Comparison of low-dose dobutamine stress echocardiography and echocardiography during glucose-insulin-potassium infusion for detection of myocardial viability after anterior myocardial infarction. Coronary Artery Disease. 2002: 13: 145-149.Leya F., Rauchhaus M., Anker S.D. Et al. Non-invasive assessment of vascular function. Paradoxal vascular response to intravenous glucose in coronary heart disease. Pur. Heart J. 2000; 21: 39-44.Leya F., Rauchhaus M., Anker S.D. Et al. Non-invasive assessment of vascular function. Paradoxal vascular response to intravenous glucose in coronary heart disease. Pur. Heart J. 2000; 21: 39-44.Nava P., Carbo R., Cuarner V. Coronary and femoral arterial contraction with high glucose, insulin, and glucose-insulin-potassium solution: effects of hypoxia. Heart and vessels. 2002; 16: 57-63.Nava P., Carbo R., Cuarner V. Coronary and femoral arterial contraction with high glucose, insulin, and glucose-insulin-potassium solution: effects of hypoxia. Heart and vessels. 2002; 16: 57-63.Lee K.S., Marwick Т.Н., Cook S.A. et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy oi medical therapy and revascularization. Circulation. 1994; 90: 2687-2694.Lee K.S., Marwick Т.Н., Cook S.A. et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy oi medical therapy and revascularization. Circulation. 1994; 90: 2687-2694.Nijland F., Kamp O., Verhorst P.M. et al. In-hospital and long-term prognostic value of viable myocardium detected by dobutamine echocardiography early after acute myocardial infarction and its relation to indicators of left ventricular systolic dysfunction. Am. J. Cardiol. 2001: 88: 949-955.Nijland F., Kamp O., Verhorst P.M. et al. In-hospital and long-term prognostic value of viable myocardium detected by dobutamine echocardiography early after acute myocardial infarction and its relation to indicators of left ventricular systolic dysfunction. Am. J. Cardiol. 2001: 88: 949-955.

The authors declare that there are no conflicts of interest present.